{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for clindamycin root_protein_modifications_structuralModifications_molecularFragment_refPname in Protein Structural Modification Substance Name (approximate match)
Status:
Investigational
Source:
NCT02494154: Not Applicable Interventional Unknown status Respiratory Failure
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03708211: Phase 1 Interventional Completed Neoplasms, Advanced Solid
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02598648: Not Applicable Interventional Unknown status Acute Respiratory Distress Syndrome
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04262479: Phase 2 Interventional Completed Latent Autoimmune Diabetes in Adults
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00791570: Phase 1 Interventional Completed Neovascular Maculopathy
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02672163: Not Applicable Interventional Completed Heart Failure
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03249207: Phase 3 Interventional Active, not recruiting Subarachnoid Hemorrhage
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01487915: Phase 2 Interventional Unknown status Advanced Urothelial Carcinoma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00996255: Phase 1 Interventional Terminated Advanced/Metastatic Solid Tumors
(2006)
Source URL:
Class:
PROTEIN
Targets:
Conditions:
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 uM. In colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 uM indicating that it has efficient and prolonged antiproliferative activity. PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation. PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo.
